Holen Sie sich die Stockscreener-App
2.65
0.00%
0.00
Handel nachbörslich:
2.61
-0.04
-1.51%
Schlusskurs vom Vortag:
$2.65
Offen:
$2.66
24-Stunden-Volumen:
2.50M
Relative Volume:
1.14
Marktkapitalisierung:
$782.72M
Einnahmen:
$38.03M
Nettoeinkommen (Verlust:
$-146.40M
KGV:
-5.8889
EPS:
-0.45
Netto-Cashflow:
$-121.38M
1W Leistung:
-15.87%
1M Leistung:
-7.67%
6M Leistung:
-27.20%
1J Leistung:
-40.72%
1-Tages-Spanne:
$2.59
$2.71
1-Wochen-Bereich:
$2.57
$3.09
52-Wochen-Spanne:
$2.335
$6.055
Abcellera Biologics Inc Stock (ABCL) Company Profile
Firmenname
Abcellera Biologics Inc
Sektor
Branche
Telefon
(604) 559-9005
Adresse
2215 YUKON STREET, VANCOUVER
Vergleichen Sie ABCL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ABCL | 2.65 | 782.72M | 38.03M | -146.40M | -121.38M | -0.45 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-02-28 | Eingeleitet | Cowen | Outperform |
| 2022-12-15 | Eingeleitet | Goldman | Buy |
| 2022-11-16 | Eingeleitet | Truist | Buy |
| 2021-12-21 | Eingeleitet | The Benchmark Company | Buy |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-01-05 | Eingeleitet | Berenberg | Buy |
| 2021-01-05 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-05 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | Stifel | Buy |
Alle ansehen
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Baillie Gifford & Co. - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Bloom Burton Cuts Earnings Estimates for AbCellera Biologics - MarketBeat
Adv Micro Devices (AMD-Q) QuotePress Release - The Globe and Mail
Abcellera Biologics Inc (ABCL-Q) QuotePress Release - The Globe and Mail
Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 - Business Wire
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St
Leerink Partnrs Has Pessimistic View of ABCL FY2024 Earnings - MarketBeat
AbCellera Unveils Breakthrough T-Cell Platform Data, Shows Promise in Cancer Treatment | ABCL Stock News - StockTitan
AbCellera Biologics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Given "Hold" Rating at Benchmark - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Given "Buy" Rating at Stifel Nicolaus - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down After Earnings Miss - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
AbCellera stock price target cut, keeps Outperform on strategic pivot By Investing.com - Investing.com UK
AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Call Transcript - Insider Monkey
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates - MSN
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Earnings call: AbCellera reports steady Q3 2024 revenue amidst R&D growth - Investing.com
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Developments - GuruFocus.com
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
AbCellera Reports Q3 2024 Business Results - The Globe and Mail
AbCellera Biologics Reports Q3 2024 Financial Results - TipRanks
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript - Nasdaq
Nasdaq Insurance Index (INSR) QuotePress Release - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Abcellera Biologics earnings beat, revenue fell short of estimates By Investing.com - Investing.com UK
AbCellera Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
McDonald's Corp (MCD-N) QuotePress Release - The Globe and Mail
Laureate Education Inc (LAUR-Q) QuotePress Release - The Globe and Mail
AbCellera Biologics Inc (ABCL) Q3 2024: Everything You Need To K - GuruFocus.com
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail
AbCellera Biologics (ABCL) Set to Announce Quarterly Earnings on Monday - MarketBeat
TSX Renewable and Clean Tech Index (TXCT) QuotePress Release - The Globe and Mail
AbCellera to Present at Upcoming Investor Conferences in November 2024 - Business Wire
3 Promising Penny Stocks On US Exchanges With Over $600M Market Cap - Yahoo Finance
Is AbCellera Biologics Inc. (ABCL) the Penny Stock with the Biggest Upside Potential According to Analysts? - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Shares Down 5%Here's What Happened - MarketBeat
AbCellera: A Platform To Pipeline Transition - Seeking Alpha
AbCellera Biologics (NASDAQ:ABCL) Trading Up 5.2%Here's What Happened - MarketBeat
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 - Lucknow Sentinel
Dark Forest Capital Management LP Buys 45,721 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Acquired by Renaissance Technologies LLC - MarketBeat
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives $14.20 Average Price Target from Analysts - MarketBeat
Wall Street SWOT: AbCellera stockBiotech firm's platform shows promise amid challenges - Investing.com
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - BioSpace
Finanzdaten der Abcellera Biologics Inc-Aktie (ABCL)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):